Adverse event profiles of hypomagnesemia caused by proton pump inhibitors using the Japanese Adverse Drug Event Report (JADER) Database

被引:3
|
作者
Yamashiro, K. [1 ]
Hosomi, K. [2 ]
Yokoyama, S. [2 ]
Ogata, F. [1 ]
Nakamura, T. [1 ]
Kawasaki, N. [1 ]
机构
[1] Kindai Univ, Fac Pharm, Lab Publ Hlth, 3-4-1 Kowakae, Higashiosaka, Osaka 5778502, Japan
[2] Kindai Univ, Fac Pharm, Div Drug Informat, Osaka, Japan
来源
PHARMAZIE | 2022年 / 77卷 / 7-9期
关键词
MAGNESIUM; RANITIDINE; OMEPRAZOLE; BIAS;
D O I
10.1691/ph.2022.2416
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Proton pump inhibitors (PPIs) are commonly used for the prevention or treatment of gastric ulcers, but they can induce hypomagnesemia. Little is known about the onset duration and risk factors related to patient charac-teristics of this adverse event in Japanese patients. Therefore, we analyzed the time-to-onset of PPI-induced hypomagnesemia and evaluated the association between hypomagnesemia and PPIs using the Japanese Adverse Drug Event Report (JADER) database. We analyzed hypomagnesemia cases between 2004 and 2021. The time-to-onset analysis was performed using the Weibull distribution, and the adjusted reporting odds ratio (aROR) or 95% confidence interval (95% CI) was calculated using a multiple logistic regression analysis. The analysis database comprised 236,525 cases, with 188 cases associated with hypomagnesemia. The median onset duration (interquartile range) of PPI-induced hypomagnesemia was 99.0 (51.8-285.5) days, which is considered the random failure type. The multiple logistic regression analysis revealed that hypomagnesemia is significantly associated with male sex (aROR, 95% CI: 1.66, 1.23-2.25), age < 60 (1.59, 1.14-2.21), estimated body-mass index (eBMI) (0.94, 0.91-0.98), PPIs (1.66, 1.18-2.30), and the interaction of age (<60)*PPIs (1.58, 1.13-2.19). However, diuretics were not significantly associated with hypomagnesemia. Our results suggest that serum magnesium levels should be measured regularly regardless of the duration of PPI use, especially in patients with male sex, age < 60, or low BMI. These findings will assist health professionals in the adequate use of PPIs. These findings need to be evaluated by cohort studies and long-term clinical investigations.
引用
收藏
页码:243 / 247
页数:5
相关论文
共 50 条
  • [41] Adverse Drug Events Caused by Drugs Contraindicated for Coadministration Reported in the Japanese Adverse Drug Event Report Database and Recognized by Reporters
    Negishi, Akio
    Oshima, Shinji
    Horii, Norimitsu
    Mutoh, Mizue
    Inoue, Naoko
    Numajiri, Sachihiko
    Ohshima, Shigeru
    Kobayashi, Daisuke
    BIOLOGICAL & PHARMACEUTICAL BULLETIN, 2021, 44 (07) : 932 - 936
  • [42] Adverse Event Trends Associated with OTC Analgesic and Antipyretic Drug: Data Mining of the Japanese Adverse Drug Event Report Database
    Hasegawa, Shiori
    Hatahira, Haruna
    Naganuma, Misa
    Shimauchi, Akari
    Sasaoka, Sayaka
    Motooka, Yumi
    Fukuda, Akiho
    Abe, Junko
    Nakao, Satoshi
    Kato, Yamato
    Ohmori, Tomofumi
    Iguchi, Kazuhiro
    Nakamura, Mitsuhiro
    YAKUGAKU ZASSHI-JOURNAL OF THE PHARMACEUTICAL SOCIETY OF JAPAN, 2017, 137 (10): : 1301 - 1311
  • [43] Fluoropyrimidine usage in cases with hyperammonemia: real-world data study using the Japanese Adverse Drug Event Report (JADER) database
    Oura, Mitsuaki
    Oguro, Fumiya
    Agatsuma, Nobukazu
    Imamaki, Hirotaka
    Nishikawa, Yoshitaka
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2023, 92 (01) : 7 - 14
  • [44] Fluoropyrimidine usage in cases with hyperammonemia: real-world data study using the Japanese Adverse Drug Event Report (JADER) database
    Mitsuaki Oura
    Fumiya Oguro
    Nobukazu Agatsuma
    Hirotaka Imamaki
    Yoshitaka Nishikawa
    Cancer Chemotherapy and Pharmacology, 2023, 92 : 7 - 14
  • [45] Analysis of anticholinergic adverse effects using two large databases: The US Food and Drug Administration Adverse Event Reporting System database and the Japanese Adverse Drug Event Report database
    Nagai, Junko
    Ishikawa, Yoichi
    PLOS ONE, 2021, 16 (12):
  • [46] Differences in the Adverse Event Profiles of Sodium-Glucose Cotransporter 2 Inhibitors used in Patients with Diabetes Mellitus and Heart Failure: An Analysis Using the Japanese Adverse Drug Event Report Database
    Sakamoto, Toshiaki
    Miyamoto, Hirotaka
    Hashizume, Junya
    Akamatsu, Hayato
    Akagi, Tomoaki
    Kodama, Yukinobu
    Hamano, Hirofumi
    Zamami, Yoshito
    Ohyama, Kaname
    CLINICAL DRUG INVESTIGATION, 2024, 44 (10) : 761 - 771
  • [47] COMPARISON OF ADVERSE EVENTS (AES) RELATED TO MAJOR ANTI-RHEUMATIC DRUGS, REPORTED TO THE OFFICIAL JAPANESE ADVERSE DRUG EVENT REPORT DATABASE (JADER)
    Tsuda, N.
    Inokuma, S.
    Noguchi, H.
    Yamaji, M.
    Harada, T.
    Misaki, M.
    Masui, Y.
    Kano, T.
    ANNALS OF THE RHEUMATIC DISEASES, 2022, 81 : 1318 - 1318
  • [48] Analysis of drug adverse events in elderly patients based on the Japanese Adverse Drug Event Report Database
    Okada, Akira
    Sera, Shoji
    Taguchi, Maho
    Yamada, Hiroaki
    Nagai, Naomi
    JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS, 2022, 47 (08) : 1264 - 1269
  • [49] Progressive multifocal leukoencephalopathy analyzed using the Japanese Adverse Drug Event Report database
    Sakurai, Shuji
    Maezawa, Mika
    Nakao, Satoshi
    Hirofuji, Sakiko
    Miyasaka, Koumi
    Yamashita, Moe
    Matsui, Kensuke
    Nishida, Shohei
    Kobayashi, Ryo
    Iguchi, Kazuhiro
    Hayashi, Yuichi
    Suzuki, Akio
    Nakamura, Mitsuhiro
    JOURNAL OF THE NEUROLOGICAL SCIENCES, 2023, 455
  • [50] Disproportionality Analysis of Safety Signals for a Wide Variety of Opioid-Related Adverse Events in Elderly Patients Using the Japanese Adverse Drug Event Report (JADER) Database
    Omoto, Takashi
    Asaka, Junichi
    Sakai, Takamasa
    Sato, Fumihiko
    Goto, Nobuyuki
    Kudo, Kenzo
    BIOLOGICAL & PHARMACEUTICAL BULLETIN, 2021, 44 (05) : 627 - 634